Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Alvotech or Aurinia Pharmaceuticals Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Alvotech and Aurinia Pharmaceuticals Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Alvotech and Aurinia Pharmaceuticals Inc.

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn’s disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Latest Biotechnology and Alvotech, Aurinia Pharmaceuticals Inc. Stock News

As of September 21, 2026, Alvotech had a $2.1 billion market capitalization, compared to the Biotechnology median of $269.5 million. Alvotech’s stock is NA in 2026, NA in the previous five trading days and down 24.81% in the past year.

Currently, Alvotech does not have a price-earnings ratio. Alvotech’s trailing 12-month revenue is $494.6 million with a -36.3% net profit margin. Year-over-year quarterly sales growth most recently was -20.3%. Analysts expect adjusted earnings to reach $-0.018 per share for the current fiscal year. Alvotech does not currently pay a dividend.

Currently, Aurinia Pharmaceuticals Inc.’s price-earnings ratio is 7.2. Aurinia Pharmaceuticals Inc.’s trailing 12-month revenue is $311.5 million with a 100.8% net profit margin. Year-over-year quarterly sales growth most recently was 18.9%. Analysts expect adjusted earnings to reach $0.944 per share for the current fiscal year. Aurinia Pharmaceuticals Inc. does not currently pay a dividend.

How We Compare Alvotech and Aurinia Pharmaceuticals Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Alvotech and Aurinia Pharmaceuticals Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Alvotech and Aurinia Pharmaceuticals Inc. Growth Grades

Company	Ticker	Growth
Alvotech	ALVO	F
Aurinia Pharmaceuticals Inc.	AUPH	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Alvotech has a Growth Score of 19, which is Very Weak. Aurinia Pharmaceuticals Inc. has a Growth Score of 26, which is Weak.

The Growth Stock Winner: No Clear Winner

Neither Alvotech or Aurinia Pharmaceuticals Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Alvotech or Aurinia Pharmaceuticals Inc. is the better investment when it comes to sustainable growth.

Alvotech and Aurinia Pharmaceuticals Inc.’s Momentum Grades

Company	Ticker	Momentum
Alvotech	ALVO	B
Aurinia Pharmaceuticals Inc.	AUPH	C

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Alvotech has a Momentum Score of 77, which is Strong. Aurinia Pharmaceuticals Inc. has a Momentum Score of 59, which is Average.

The Momentum Grade Winner: Alvotech

As you can clearly see from the Momentum Grade breakdown above, Alvotech is considered to have stronger momentum compared to Aurinia Pharmaceuticals Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Alvotech could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Alvotech and Aurinia Pharmaceuticals Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Alvotech	ALVO	F
Aurinia Pharmaceuticals Inc.	AUPH	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Alvotech has a Earnings Estimate Score of 5, which is Very Negative. Aurinia Pharmaceuticals Inc. has a Earnings Estimate Score of 40, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Alvotech or Aurinia Pharmaceuticals Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Alvotech or Aurinia Pharmaceuticals Inc. is the better investment when it comes to estimate revisions.

Other Alvotech and Aurinia Pharmaceuticals Inc. Grades

In addition to Estimate Revisions, Momentum and Growth, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Alvotech and Aurinia Pharmaceuticals Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Alvotech or Aurinia Pharmaceuticals Inc. Stock?

Overall, Alvotech stock has a Growth Score of 19, Momentum Score of 77 and Estimate Revisions Score of 5.

Aurinia Pharmaceuticals Inc. stock has a Growth Score of 26, Momentum Score of 59 and Estimate Revisions Score of 40.

Comparing Alvotech and Aurinia Pharmaceuticals Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.